Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 16/20 | 0.61 |
| ▸ | AXL | P30530 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.52 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.52 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853032 | 0.85 | SLC22A12 (0.58) | SLC22A12AXLCYP2C9SLC22A6SLC22A8 | |
| SCHEMBL13852799 | 0.84 | SLC22A12 (0.54) | SLC22A12 | |
| SCHEMBL13615174 | 0.83 | SLC22A12 (0.78) | SLC22A12AXLCYP2C9SLC22A6SLC22A8 | |
| SCHEMBL13615039 | 0.83 | SLC22A12 (0.65) | SLC22A12AXLCYP2C9SLC22A6SLC22A8 | |
| SCHEMBL26075672 | 0.81 | SLC22A12 (0.69) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL13852803 | 0.80 | HSD17B2 (0.58) | CYP3A4 | |
| SCHEMBL15486381 | 0.80 | SLC22A12 (0.77) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL13852848 | 0.79 | SLC22A12 (0.54) | SLC22A12AXL | |
| SCHEMBL13615295 | 0.77 | ALDH1A1 (0.57) | SLC22A12 | |
| SCHEMBL6974728 | 0.77 | HTR6 (0.69) | SLC22A12AXLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | SLC22A12 4663/4885AXL 98/4885CYP2C9 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.